Ankur Mutreja | Director of External Affairs and Health Security
South Asia-PATH

Ankur Mutreja, Director of External Affairs and Health Security, South Asia-PATH

Dr Ankur Mutreja, PhD, FRSB is currently a Director of External Affairs and Health Security at PATH operating from the UK and India. An experienced global health professional who has worked in industry, academia and public health, Dr Mutreja has significant expertise in R&D translation, tech-transfer, strategy, contract negotiation, tailored communication, and policy recommendation. In his previous role at CEPI where he was the country in-charge for India and Head of Global South Partnerships portfolio, he played an instrumental role in integrating R&D, Manufacturing, Access, Partnerships, Communications and Resource Mobilization plans of CEPI into a Global South Strategic Roadmap. Prior to CEPI, as a Group Leader of Global Health, he led a large international team of managers, scientists, and policy experts at the University of Cambridge where he managed several public health projects in vaccines, diagnostics, WASH, surveillance, and epidemiology. He has also served in the roles of Project Leader at the MSD-Wellcome Hilleman Laboratories and Industry-Academia Bridging Fellow at the Novartis Vaccines for Global Health, with a mission of making affordable vaccines suitable for LMIC needs. In his career, he has successfully raised funds, led, and delivered on large programs from Wellcome, WHO, BMGF, MRC, ESRC, TSB, Innovate UK, NIHR, BRC, Alborada Trust, DBT, ICMR and Hamied Foundation, among several others. Dr Mutreja has an excellent publication record and is on the board of and holds honorary positions at numerous key institutions and agencies of high repute.

Appearances:



Day 3 - Thursday 16th October @ 10:30

Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era

  • Systemic investment barriers to vaccine investment; high R&D costs, uncertain returns, market distortions, and socio-political linked demand uncertainty impact vaccine investment
  • The impacts of fiscal austerity, the rise of transactional aid, and shifting priorities on transitional funding methods, partnerships and equitable access
  • How to incentivise R&D in this evolving landscape to prevent innovation stalling and accelerate breakthroughs
  • Exploring sustainable, scalable solutions to fill the gap left by declining public-sector funding; blended finance, pooled procurement, and value-based pricing
  • Real world case studies: GAVI’s AMC, CEPI’s equity clauses, pharma-NGO coalitions
last published: 06/Aug/25 15:15 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2025

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com

 

Otto Squire
Otto.Squire@terrapinn.com

 

TO SPEAK


Isla Sutherland

Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.